Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

45.15 -0.63 (-1.38%)
Official Closing Price Updated: 4:10 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,218,432
Open 45.75
Bid (Size) 44.76 (9)
Ask (Size) 45.20 (9)
Prev. Close 45.78
Today's Range 44.94 - 45.77
52wk Range 33.33 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.20%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements. 
Via Benzinga
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen,... 
Via Benzinga
Topics Lawsuit Whistleblower
Exposures Financial Legal

Performance

YTD
+20.37%
+20.37%
1 Month
+11.23%
+11.23%
3 Month
+7.65%
+7.65%
6 Month
+28.27%
+28.27%
1 Year
+27.47%
+27.47%

More News

Read More
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Via Benzinga
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
Via Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
Via InvestorPlace
Amazon Pours ~$1.3B Investment Into French Operations: Report
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
Via Benzinga
Exposures Product Safety
Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine
Via Investor's Business Daily
Exposures Product Safety
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Via Benzinga
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout?
Via Investor's Business Daily
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
Via InvestorPlace
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Via Benzinga
Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally
Via Benzinga
Topics Economy
Exposures Interest Rates
Forget the Fed. These 3 Stocks Will Soar No Matter What
Via InvestorPlace
Topics Economy
Exposures Interest Rates
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Via Benzinga
Topics Brexit
Exposures Brexit
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Via Benzinga
GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
Via Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.